Completed PHASE4 INTERVENTIONAL 1-arm NCT02309281

Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab

Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab

Sponsor: Bayer

Conditions Neovascular Age-related Macular Degeneration

Interventions aflibercept 2mg

Updated 6 times since 2017 Last updated: Oct 11, 2018 Started: May 31, 2013 Primary completion: May 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Neovascular Age-related Macular Degeneration, this trial is completed. The trial is conducted by Bayer and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Nov 2018 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Nov 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Vista Klinik

Data source: Vista Klinik

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.